|Articles|July 1, 2002

Intravitreal triamcinolone for AMD appears promising, but more studies needed

Author(s)Laszlo Dosa

Fort Lauderdale, FL-Intravitreal triamcinolone appears to inhibit the growth of choroidal neovascularization (CNV) and reduce subretinal fluid in the short term, but it needs further evaluation, ac-cording to Mark Gillies, MB, BS, PhD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME